AAAAAA
Results:
1-7
|
Results: 7
Authors:
Frohlich, J
Dobiasova, M
Lear, S
Won, K
Lee, J
Citation: J. Frohlich et al., The role of risk factors in the development of atherosclerosis, CR R CL LAB, 38(5), 2001, pp. 401-440
Authors:
Dobiasova, M
Raslova, K
Rauchova, H
Vohnout, B
Ptackova, K
Frohlich, J
Citation: M. Dobiasova et al., Atherogenic lipoprotein profile in families with and without history of early myocardial infarction, PHYSL RES, 50(1), 2001, pp. 1-8
Authors:
Raslova, K
Nagyova, A
Dobiasova, M
Ptackova, K
Dusinska, M
Citation: K. Raslova et al., Effect of ciprofibrate on lipoprotein metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype, ACT DIABETO, 37(3), 2000, pp. 131-134
Authors:
Dobiasova, M
Adler, L
Ohta, T
Frohlich, J
Citation: M. Dobiasova et al., Effect of labeling of plasma lipoproteins with [H-3]cholesterol on values of esterification rate of cholesterol in apolipoprotein B-depleted plasma, J LIPID RES, 41(8), 2000, pp. 1356-1357
Authors:
Dobiasova, M
Frohlich, JJ
Citation: M. Dobiasova et Jj. Frohlich, Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport, CLIN CHIM A, 286(1-2), 1999, pp. 257-271
Authors:
Dobiasova, M
Frohlich, J
Citation: M. Dobiasova et J. Frohlich, Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio, PHYSL RES, 47(6), 1998, pp. 387-397
Authors:
Raslova, K
Dobiasova, M
Nagyova, A
Fabry, R
Rauchova, H
Dusinska, M
Citation: K. Raslova et al., Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype:effects on HDL quality, LDL susceptibility to oxidation and DNA damage, EUR J CL PH, 54(9-10), 1998, pp. 697-699
Risultati:
1-7
|